Mechanisms of disease: epithelial-mesenchymal transition - does cellular plasticity fuel neoplastic progression?
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Epithelial-mesenchymal transition (EMT) is a phenotypic conversion that facilitates organ morphogenesis and tissue remodeling in physiological processes, such as embryonic development and wound healing. A similar phenotypic conversion is also detected in fibrotic diseases and neoplasia, and is associated with disease progression. EMT in cancer epithelial cells often seems to be an incomplete and bidirectional process. In this Review, we discuss the phenomenon of EMT as it pertains to tumor development, focusing on exceptions to the commonly held rule that EMT promotes invasion and metastasis. We also highlight the role of RAS-controlled signaling mediators, ERK1, ERK2 and phosphatidylinositol 3-kinase, as microenvironmental responsive regulators of EMT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MSCs facilitate and modulate EMT through the production of regulatory molecules, namely TGF-b, E-cadherin and micro-RNA, resulting in more invasive phenotype [46], [47].”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 1×
“70-gene prognostic signature CCL2, MT1X and MT2A van‘t Veer et al. (2002)46”
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Complex networks orchestrate epithelial–mesenchymal transitions
Thiery, J. P., & Sleeman, J. P. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1835 · Cited by 3,958
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,649
The epithelial–mesenchymal transition: new insights in signaling, development, and disease
Lee, J. M., Dedhar, S., Kalluri, R., & Thompson, E. W. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200601018 · Cited by 2,019
Molecular requirements for epithelial–mesenchymal transition during tumor progression
Huber, M. A., Kraut, N., & Beug, H. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.08.001 · Cited by 1,821
Epithelial–mesenchymal transitions in development and pathologies
Thiery, J. P. (2003) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2003.10.006 · Cited by 1,704
TGF-β and epithelial-to-mesenchymal transitions
Zavadil, J., & Böttinger, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208927 · Cited by 1,578
An Overview of Epithelio-Mesenchymal Transformation
Hay, E. D. (1995) · Cells Tissues Organs · doi:10.1159/000147748 · Cited by 1,567
The Snail genes as inducers of cell movement and survival: implications in development and cancer
Barrallo-Gimeno, A., & Nieto, M. A. (2005) · Development · doi:10.1242/dev.01907 · Cited by 1,394
Cited by
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., Rusu, A., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 944
“The responsiveness of RAS in the TME frequently implies a phenotypic modification of the tumor cell toward a migratory status, through the loss of cell-to-cell adhesion via EMT and its related effectors in tumor cells [83].”
BackgroundInfluentialUlrich, T. A., de Juan Pardo, E. M., & Kumar, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4859 · Cited by 901
“Importantly, many of these pathways have also been implicated in epithelial-mesenchymal transition (48).”
BackgroundFGF Receptors: Cancer Biology and Therapeutics: CANCER BIOLOGY AND THERAPEUTICS ON FGF RECEPTORS
Katoh, M., & Nakagama, H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21288 · Cited by 610
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14
Wang, H., Li, Z.-Y., Liu, Y., Persson, J., Beyer, I., Möller, T., Koyuncu, D., Drescher, M. R., Strauss, R., Zhang, X.-B., et al. (2011) · Nature Medicine · doi:10.1038/nm.2270 · Cited by 432
“EMT is characterized by increased expression of mesenchymal markers, increased expression of extracellular matrix compounds, decreased expression of epithelial markers, altered location of transcription factors, and activation of kinases 7.”
Yang, S., Liu, Y., Li, M.-Y., Ng, C. S. H., Yang, S.-L., Wang, S., Zou, C., Dong, Y., Du, J., Long, X., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0700-1 · Cited by 414
“HEK-293T cells were co-transfected with the indicated plasmids with lipofectamine 2000 (Invitrogen), and the nuclear and cytoplasmic proteins were extracted as previously described [19, 20].”
BackgroundMethodImmune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells
Santisteban, M., Reiman, J. M., Asiedu, M. K., Behrens, M. D., Nassar, A., Kalli, K. R., Haluska, P., Ingle, J. N., Hartmann, L. C., Manjili, M. H., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3343 · Cited by 379
“These results are consistent with the observation that EMT is associated with some, but not all, genetic changes ordinarily associated with the stromal or mesenchymal phenotype (39).”
ResultSelf-citationHyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities
Toole, B. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0479 · Cited by 362
The Epithelial-to-Mesenchymal Transition and Cancer Stem Cells: A Coalition Against Cancer Therapies
Hollier, B. G., Evans, K., & Mani, S. A. (2009) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-009-9110-3 · Cited by 353
“Although the EMT program is necessary for normal development, the aberrant activation of EMT contributes to various pathologic conditions, including fibrosis and carcinoma progression [22, 23].”
BackgroundHärmä, V., Virtanen, J., Mäkelä, R., Happonen, A., Mpindi, J.-P., Knuuttila, M., Kohonen, P., Lötjönen, J., Kallioniemi, O., & Nees, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010431 · Cited by 344
“EMT as a developmental mechanism could be involved in normal developmental processes and invasive cancers alike, and likely represents a bidirectional process (EMT versus MET) [63].”
BackgroundMechanisms and impact of altered tumour mechanics
Mohammadi, H., & Sahai, E. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0131-2 · Cited by 336
Apoptotic cell signaling in cancer progression and therapy
Plati, J., Bucur, O., & Khosravi-Far, R. (2011) · Integrative Biology · doi:10.1039/c0ib00144a · Cited by 319
Tissue architecture and function: dynamic reciprocity via extra- and intra-cellular matrices
Xu, R., Boudreau, A., & Bissell, M. J. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9178-z · Cited by 312
“Hyaluronan, a non-sulfated glycosaminoglycan, is localized at the tip of terminal end buds and is mainly produced by ‘cap cells’ [12, 13], which may contribute to cell proliferation and migration.”
Self-citationDysregulation of apoptosis in hepatocellular carcinoma cells
Fabregat, I. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.513 · Cited by 280
Cancer Stem Cells, Hypoxia and Metastasis
Hill, R. P., Marie-Egyptienne, D. T., & Hedley, D. W. (2009) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2008.12.002 · Cited by 238
Chen, C., Wei, Y., Hummel, M., Hoffmann, T. K., Gross, M., Kaufmann, A. M., & Albers, A. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016466 · Cited by 235
“Although the EMT program is necessary for normal development, the aberrant activation of EMT contributes to various pathologic conditions, including fibrosis and carcinoma progression [25,26].”
BackgroundTaylor, M. A., Parvani, J. G., & Schiemann, W. P. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9181-1 · Cited by 231
ERK1/2 Regulation of CD44 Modulates Oral Cancer Aggressiveness
Judd, N. P., Winkler, A. E., Murillo-Sauca, O., Brotman, J. J., Law, J. H., Lewis, J. S., Dunn, G. P., Bui, J. D., Sunwoo, J. B., & Uppaluri, R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1831 · Cited by 221
“Others have shown that ERK1/2 is associated with EMT, which itself is associated with CD44 expression Research. on September 2, 2017.”
InfluentialSureban, S. M., May, R., Lightfoot, S. A., Hoskins, A. B., Lerner, M., Brackett, D. J., Postier, R. G., Ramanujam, R., Mohammed, A., Rao, C. V., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2738 · Cited by 214
“suggest that DCAMKL-1 expressing cells may be undergoing EMT (27).”
Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression
Wendt, M. K., Tian, M., & Schiemann, W. P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1199-1 · Cited by 210
“…the initiation of EMT programs elicits the selection and expansion of CSCs (Ben- Porath et al. 2008; Morel et al. 2008; Shipitsin et al. 2007), leading to the development of chemoresistant phenotypes and disease recurrence (Creighton et al. 2010; Singh and Settleman 2010; Turley et al. 2008).”
Capparuccia, L., & Tamagnone, L. (2009) · Journal of Cell Science · doi:10.1242/jcs.030197 · Cited by 206
“Dysregulated activation of EMT is typically observed in carcinomas and it is often associated with progression to malignancy (Nishimura and Sasaki, 2008; Turley et al., 2008).”
BackgroundStrauss, R., Li, Z.-Y., Liu, Y., Beyer, I., Persson, J., Sova, P., Möller, T., Pesonen, S., Hemminki, A., Hamerlik, P., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016186 · Cited by 194
“EMT is characterized by increased expression of mesenchymal markers (vimentin, thrombospondin, N-cadherin, vitronectin), increased expression of extracellular matrix compounds (collagen IV and fibronectin), decreased expression of epithelial markers (Ecadherin, Occludin, Desmoplakin, and Mucin1), altered location of t…”
BackgroundInfluentialThe relevance of the TGF-β Paradox to EMT-MET programs
Morrison, C. D., Parvani, J. G., & Schiemann, W. P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.048 · Cited by 183
FOXM1 (Forkhead box M1) in Tumorigenesis
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00016-2 · Cited by 184
“…2010; Tarin, 2005; Thiery, 2002, 2003; Thiery and Sleeman, 2006; Thiery et al., 2009; Thompson and Newgreen, 2005; Tse and Kalluri, 2007; Tsuji et al., 2009; Turley et al., 2008; Voulgari and Pintzas, 2009; Yang and Weinberg, 2008; Yilmaz and Christofori, 2009, 2010; Zavadil and Böttinger, 2005).”
Wang, H., Wu, Q., Liu, Z., Luo, X., Fan, Y., Liu, Y., Zhang, Y., Hua, S., Fu, Q., Zhao, M., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.122 · Cited by 182
“Morphologic and phenotypic EMT-like changes are accompanied by the downregulation of epithelial marker E-cadherin and upregulation of mesenchymal markers, such as Vimentin, N-cadherin, MMP-2, and MMP-9.(16,17) We examined the expression of epithelial and mesenchymal markers in FAP-silenced KB cells and found decreased…”
BackgroundFei, F., Zhang, D., Yang, Z., Wang, S., Wang, X., Wu, Z., Wu, Q., & Zhang, S. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0277-8 · Cited by 177
“EMT is known as a cadherin switching process, leading to primary molecular changes, including the loss of epithelial cell markers and overexpression of mesenchymal cell markers [43–45].”
BackgroundLiang, Y.-J., Ding, Y., Levery, S. B., Lobaton, M., Handa, K., & Hakomori, S.-I. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302825110 · Cited by 174
“These observations are in accordance with previous reports (20, 35); therefore, we compared GSL expression profiles in the HMLE-Twist-ER cells and in HMLE-Twist-ER cells cultured in the presence of tamoxifen as breast non-CSCs and CSCs, respectively.”
MethodResultThe epithelial polarity program: machineries involved and their hijacking by cancer
Tanos, B., & Rodriguez-Boulan, E. (2008) · Oncogene · doi:10.1038/onc.2008.345 · Cited by 174
“…cells into invasive migratory cells requires loss of epithelial junctions and changes in the MT and actin cytoskeletons , a process known as epithelial–mesenchymal transition (EMT) (for review see Thiery, 2002; Wodarz and Nathke, 2007; Turley et al., 2008; Moreno-Bueno et al., 2008) (Figure 6).”
BackgroundOswald, L., Grosser, S., Smith, D. M., & Käs, J. A. (2017) · Journal of Physics D: Applied Physics · doi:10.1088/1361-6463/aa8e83 · Cited by 173
“EMT is reported to play a role in tissue repair, inflammation and tumour progression [18], however, its role in cancer is still debated since it is neither a necessary nor a sufficient marker for malignant behaviour [21].”
BackgroundCao, M.-X., Jiang, Y.-P., Tang, Y.-L., & Liang, X.-H. (2017) · Oncotarget · doi:10.18632/oncotarget.13957 · Cited by 165
“Given that emerging evidence has supported that de-differentiation of cancer cells through EMT with enhanced motility and dissemination, and re-differentiation through MET with colonization are critical in the course of multi-stage tumor progression, targeting EMT plasticity is thought to be a promising way to treat m…”
BackgroundHoffman, G. E., Hartley, B. J., Flaherty, E., Ladran, I., Gochman, P., Ruderfer, D. M., Stahl, E. A., Rapoport, J., Sklar, P., & Brennand, K. J. (2017) · Nature Communications · doi:10.1038/s41467-017-02330-5 · Cited by 160
CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1
Liu, T., Yu, J., Deng, M., Yin, Y., Zhang, H., Luo, K., Qin, B., Li, Y., Wu, C., Ren, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms13923 · Cited by 161
Sureban, S. M., May, R. J., Mondalek, F. G., Qu, D., Ponnurangam, S., Pantazis, P., Anant, S., Ramanujam, R. P., & Houchen, C. W. (2011) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-9-40 · Cited by 158
“Epithelial-to-Mesenchymal Transition (EMT) is a phenotypic conversion in fibrotic diseases and neoplasia [33,34].”
BackgroundSureban, S. M., May, R. J., Qu, D., Weygant, N., Chandrakesan, P., Ali, N., Lightfoot, S. A., Pantazis, P., Rao, C. V., Postier, R. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073940 · Cited by 150
“EMT is a highly conserved process, characterized by the phenotypic conversion of epithelial cells to mesenchymal cells [7].”
BackgroundThe network of epithelial–mesenchymal transition: potential new targets for tumor resistance
Nantajit, D., Lin, D., & Li, J. J. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1840-y · Cited by 150
“Changes of tumor microenvironment associated with Ras/ERK signaling could as well contribute to such phenomenon (Turley et al. 2008).”
BackgroundGuan, F., Handa, K., & Hakomori, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902368106 · Cited by 137
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer
Muggerud, A. A., Hallett, M., Johnsen, H., Kleivi, K., Zhou, W., Tahmasebpoor, S., Amini, R.-M., Botling, J., Børresen-Dale, A.-L., Sørlie, T., et al. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.06.007 · Cited by 133
“…including disruption of the myoepithelial cell layer (Hu et al., 2008; Polyak and Hu, 2005), epithelialemesenchymal transition (EMT) (Jechlinger et al., 2003; Lien et al., 2007; Turley et al., 2008), and angiogenesis (Blick et al., 2008; Rice and Quinn, 2002; Teo et al., 2003; Yu et al., 2007).”
BackgroundFreire-de-Lima, L., Gelfenbeyn, K., Ding, Y., Mandel, U., Clausen, H., Handa, K., & Hakomori, S.-I. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115191108 · Cited by 130
“We hypothesize that onfFN is involved in the “mesenchymal adhesion process” (44, 55), whereby extracellular matrix (ECM)-dependent integrin activity, and associated signal transduction are altered (for review, see ref.”
BackgroundMaitah, M. Y., Ali, S. S., Ahmad, A., Gadgeel, S. M., & Sarkar, F. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016068 · Cited by 142
RetractedD'Assoro, A. B., liu, T., Quatraro, C., Amato, A., Opyrchal, M., Leontovich, A., Ikeda, Y., Ohmine, S., Lingle, W., Suman, V, et al. (2014) · Oncogene · doi:10.1038/onc.2012.628 · Cited by 127
Chang, S., Chen, B., Wang, X., Wu, K., & Sun, Y. (2017) · BMC Cancer · doi:10.1186/s12885-017-3216-6 · Cited by 127
“Their changes correlated with EMT [14].”
Ha, G., Park, J. S., & Breuer, E.-K. Y. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.013 · Cited by 130
“Epithelial-mensenchymal transition (EMT) is a biological conversion process of polarized epithelial cells to mesenchymal phenotype, characterized by the loss of cell–cell adhesion and epithelial polarity as well as the acquisition of migratory and invasive properties [1–5].”
BackgroundOncolytic virotherapy: Challenges and solutions
Goradel, N. H., Baker, A. T., Arashkia, A., Ebrahimi, N., Ghorghanlu, S., & Negahdari, B. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100639 · Cited by 135
Ueno, K., Hazama, S., Mitomori, S., Nishioka, M., Suehiro, Y., Hirata, H., Oka, M., Imai, K., Dahiya, R., & Hinoda, Y. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605307 · Cited by 136
“In this context, FZD7 might be one of mesenchymal characteristics of colon cancer cells when they metastasise through epithelial–mesenchymal transition (Turley et al, 2008).”
BackgroundGao (2010) · International Journal of Oncology · doi:10.3892/ijo_00000715 · Cited by 118
“It has been suggested that the Snail family down-regulates E-cadherin, changes cytoskeleton directly and constructs a highly complex signal network in TGF-ß1-triggered EMT (21).”
BackgroundTakahashi, K., Ota, Y., Kogure, T., Suzuki, Y., Iwamoto, H., Yamakita, K., Kitano, Y., Fujii, S., Haneda, M., Patel, T. C., et al. (2019) · Cancer Science · doi:10.1111/cas.14232 · Cited by 119
Testing the differential adhesion hypothesis across the epithelial−mesenchymal transition
Pawlizak, S., Fritsch, A. W., Grosser, S., Ahrens, D., Thalheim, T., Riedel, S., Kießling, T. R., Oswald, L., Zink, M., Manning, M. L., et al. (2015) · New Journal of Physics · doi:10.1088/1367-2630/17/8/083049 · Cited by 122
Xu, Q., Sun, Q., Zhang, J., Yu, J., Chen, W., & Zhang, Z. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs374 · Cited by 105
Soriano, O., Pérez, M. A., Vicente‐Manzanares, M., & Castellano, E. (2021) · Genes · doi:10.3390/genes12060819 · Cited by 118
“Regarding tumor development, the RBD model demonstrated that Ras binding to PI3K is essential for the initiation of lung and skin tumors and abrogation of this interaction halted initiation of both tumor types [48] and greatly impaired tumor maintenance [55].”
BackgroundMethodPotential implications of mesenchymal stem cells in cancer therapy
Dai, L.-J., Moniri, M. R., Zeng, Z.-R., Zhou, J. X., Rayat, J., & Warnock, G. L. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.012 · Cited by 99
“The major EMT-related regulatory molecules, including E-cadherin, TGF-ß and microRNA, were described in recent review articles [92,94].”
BackgroundEpigenetic Upregulation of HGF and c-Met Drives Metastasis in Hepatocellular Carcinoma
Ogunwobi, O. O., Puszyk, W. M., Dong, H., & Liu, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063765 · Cited by 102
“Although many in vitro and animal studies have provided experimental support for this idea, some studies have questioned the usefulness of this concept in explaining cancer metastasis [4,5].”
Cdc6 expression represses E-cadherin transcription and activates adjacent replication origins
Sideridou, M., Zakopoulou, R., Evangelou, K., Liontos, M., Kotsinas, A., Rampakakis, E., Gagos, S., Kahata, K., Grabusic, K., Gkouskou, K., et al. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201108121 · Cited by 98
“We have previously made the intriguing observation that Cdc6 overexpression in premalignant, nontumorigenic mouse epithelial cells leads to malignant transformation with features of epithelial to mesenchymal transition (EMT; Liontos et al., 2007).”
InfluentialKong, G., Jiang, Y., Sun, X., Cao, Z., Zhang, G., Zhao, Z., Zhao, Y. B., Qian, Y., & Cheng, G. (2017) · Oncology Reports · doi:10.3892/or.2017.5973 · Cited by 101
“Studies have well established that EMT is a distinctive phenotypic switch by which epithelial cells lose their polarity and acquire the invasive properties of mesenchymal cells in the process of metastasis (48).”
BackgroundYe, Z., Zhou, M., Tian, B., Wu, B., & Li, J. (2015) · Europe PMC (PubMed Central) · Cited by 94
Rafehi, S., Valdes, Y. R., Bertrand, M., McGee, J., Préfontaine, M., Sugimoto, A., DiMattia, G. E., & Shepherd, T. G. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-15-0383 · Cited by 92
“It is well-established that this occurs through epithelial–mesenchymal transition (EMT), the mechanism believed to help tumor cells in their ability to migrate, invade and metastasize (Turley et al. 2008, Vergara et al. 2010).”
BackgroundLuo, X., Dong, Z., Chen, Y., Yang, L., & Lai, D. (2013) · Cell Proliferation · doi:10.1111/cpr.12038 · Cited by 96
Wang, H., Li, Z.-Y., Yumul, R., Lara, S. L., Hemminki, A., Fender, P., & Lieber, A. (2011) · Journal of Virology · doi:10.1128/jvi.00514-11 · Cited by 91
Nouri, M., Ratther, E., Stylianou, N., Nelson, C. C., Hollier, B. G., & Williams, E. D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00370 · Cited by 93
The modulation of MSC integrin expression by RGD presentation
Lam, J., & Segura, T. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.091 · Cited by 79
Zheng, H., Li, W., Wang, Y., Liu, Z., Cai, Y., Xie, T., Shi, M. Q., Wang, Z., & Jiang, B. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.03.014 · Cited by 86
The role of MTDH/AEG-1 in the progression of cancer.
Shi, X., & Wang, X. (2015) · PubMed Central · Cited by 79
Integrins in mammary-stem-cell biology and breast-cancer progression – a role in cancer stem cells?
Pontier, S. M., & Muller, W. J. (2009) · Journal of Cell Science · doi:10.1242/jcs.040394 · Cited by 79
“…version of the human oncogene ERBB2 (also known as HER-2 and NEU) is expressed under the control of a mammary-epithelium-specific promoter (Ursini-Siegel et al., 2007), the expression of a dominantnegative mutant of β4 integrin has been shown to delay ERBB2induced tumorigenesis…”
BackgroundEpithelial Junction Opener JO-1 Improves Monoclonal Antibody Therapy of Cancer
Beyer, I., van Rensburg, R., Strauss, R., Li, Z., Wang, H., Persson, J., Yumul, R., Feng, Q., Song, H., Bártek, J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2009 · Cited by 85
“Epithelial cells maintain several intercellular junctions (tight junctions, adherens junctions, gap junctions, anddesmosomes), a feature which is often conserved in epithelial cancers in situ and in cancer cell lines (5).”
Endothelial‐to‐mesenchymal transition induced by W nt 3a in keloid pathogenesis
Lee, W. J., Park, J. H., Shin, J. U., Noh, H., Lew, D. H., Yang, W. I., Yun, C., Lee, D. W., & Lee, J. H. (2015) · Wound Repair and Regeneration · doi:10.1111/wrr.12300 · Cited by 82
Forsyth, C. B., Tang, Y., Shaikh, M. W., Zhang, L., & Keshavarzian, A. (2009) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.01061.x · Cited by 77
“In addition to breast and colon cancer, evidence supports a role for EMT in oral, nasopharyngeal, esophageal, gastric, rectal, cervical, ovarian, thyroid, pancreatic, and prostate cancer to name only a partial list (Hugo et al., 2007; Natalwala et al., 2008; Turley et al., 2008).”
BackgroundInfluentialLiu, W., Huang, Y., Liu, C., Yang, Y., Liu, H., Cui, J., Cheng, Y., Gao, F., Cai, J., & Li, B. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.153 · Cited by 78
Mimeault, M., & Batra, S. K. (2008) · Ageing Research Reviews · doi:10.1016/j.arr.2008.12.001 · Cited by 85
Dong, Z., Ke, A., Li, T., Cai, J.-B., Yang, Y., Zhou, W. J., Shi, G., & Fan, J. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01361-3 · Cited by 77
“The EMT process is known to be correlated with normal and malignant mammary stem cell function [21, 22].”
BackgroundOncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy
Volovăț, S. R., Scripcariu, D. V., Vasilache, I.-A., Stolniceanu, C. R., Volovat, C. D., Augustin, I. G., Volovăț, C. C., Ostafe, M.-R., Andreea-Voichița, S.-G., Bejusca-Vieriu, T., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021180 · Cited by 94
“This approach has demonstrated efficacy in various types of tumors in preclinical and clinical settings [35].”
BackgroundZuo, J., Ishikawa, T., Boutros, S., Xiao, Z., Humtsoe, J. O., & Kramer, R. H. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0354 · Cited by 77
“The coordinated signaling generated through extracellular matrix (ECM) adhesion and growth factors are essential for normal epithelial cell survival, growth, and proliferation (3, 4).”
BackgroundInfluentialRadiation driven epithelial-mesenchymal transition is mediated by Notch signaling in breast cancer
Kim, R.-K., Kaushik, N., Suh, Y., Yoo, K.-C., Cui, Y., Kim, M.-J., Lee, H., Kim, I. G., & Lee, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10802 · Cited by 79
“EMT is controlled by multifaceted pathways in which differentiated epithelial cells undergo morphological modifications from an epithelial cobblestonelike type to an elongated mesenchymal fibroblast type including decreased expression in epithelial markers such as E-cadherin with increased expression of mesenchymal ma…”
BackgroundJeon, Y. K., Kim, C. K., Hwang, K., Park, H.-Y., Koh, J., Chung, D. H., Lee, C., & Ha, G. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.143 · Cited by 72
“mutants Akt underwent EMT along with Snail and Slug activation.(2,12,51) ERK signaling also upregulated the expression of Snail and Slug in lung cancer.”
BackgroundMesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment
Darestani, N. G., Rudova, A., Al-Gazally, M. E., Zekiy, A. O., Ansari, M. J., Zabibah, R. S., Jawad, M. A., Al-Shalah, S. A. J., Rizaev, J. A., Alnassar, Y. S., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-022-01012-0 · Cited by 115
Zhang, W., Jiang, B., Guo, Z., Sardet, C., Zou, B., Lam, C. S. C., Li, J., He, M., Lan, H. Y., Pang, R., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq094 · Cited by 71
Vimentin filaments drive migratory persistence in polyploidal cancer cells
Xuan, B., Ghosh, D., Jiang, J. J., Shao, R., & Dawson, M. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2011912117 · Cited by 75
Controlled Extracellular Matrix Degradation in Breast Cancer Tumors Improves Therapy by Trastuzumab
Beyer, I., Li, Z., Persson, J., Liu, Y., van Rensburg, R., Yumul, R., Zhang, X., Hung, M., & Lieber, A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.256 · Cited by 71
Bertrán, E., Caja, L., Navarro, E., Sancho, P., Mainez, J., Murillo, M. M., Vinyals, A., Fabra, À., & Fabregat, I. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.06.006 · Cited by 75
Micrometastasis in gastric cancer
Zhang, Z.-Y., & Ge, H. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.021 · Cited by 72
“Therefore in many studies, taking few EMT and stem markers with aberrant expression as EMT identification might not be biologically accurate [33], since evidence of these abnormal expression by direct epithelial-to-mesenchymal phenotype conversions was very limited in human tumor specimens [93].”
BackgroundZheng, H., Cai, Y. D., Wang, Y. D., Cui, X., Xie, T., Li, W. J., Peng, L., Zhang, Y., Wang, Z. Q., Wang, J., et al. (2012) · Oncogene · doi:10.1038/onc.2012.126 · Cited by 77
Stem cells in squamous head and neck cancer
Albers, A. E., Chen, C., Köberle, B., Qian, X., Klußmann, J. P., Wollenberg, B., & Kaufmann, A. M. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.03.004 · Cited by 84
“[66] Turley EA, Veiseh M, Radisky DC, Bissell MJ.”
BackgroundDong, Z., Yang, L., & Lai, D. (2013) · Cell Proliferation · doi:10.1111/cpr.12043 · Cited by 72
TACC3 Is Essential for EGF-Mediated EMT in Cervical Cancer
Ha, G., Kim, J., & Breuer, E.-K. Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070353 · Cited by 65
Inducible expression of TGFβ, Snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model
Argast, G. M., Krueger, J. S., Thomson, S., Sujka-Kwok, I., Carey, K., Silva, S., O’Connor, M., Mercado, P., Mulford, I. J., Young, G. D., et al. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9394-8 · Cited by 63
Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer
Arendt, L. M., Rugowski, D. E., Grafwallner-Huseth, T. L., Garcia-Barchino, M. J., Rui, H., & Schuler, L. A. (2011) · Breast Cancer Research · doi:10.1186/bcr2819 · Cited by 69
“The spindle shaped cell morphology, loss of cell polarity, and expression of Vim mRNA within these tumors suggest the epithelial to mesenchymal transition (EMT, for review, [44,45]).”
FOXK1 interaction with FHL2 promotes proliferation, invasion and metastasis in colorectal cancer
Wu, M., Wang, J., Tang, W., Zhan, X., Li, Y., Peng, Y., Huang, X., Bai, Y., Zhao, J., Li, A., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.68 · Cited by 61
Cassinelli, G., Favini, E., Degl'Innocenti, D., Salvi, A., De Petro, G., Pierotti, M. A., Zunino, F., Borrello, M. G., & Lanzi, C. (2009) · Neoplasia · doi:10.1593/neo.08916 · Cited by 60
Li, S., Mo, C., Peng, Q., Kang, X., Sun, C., Jiang, K., Huang, L., Yu, L., Sui, J., Qin, X. Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071273 · Cited by 61
“Recent studies demonstrated that epithelial-to-mesenchymal transition (EMT) is a critical step of tumor metastasis [2].”
BackgroundRanahan, W. P., Han, Z., Smith-Kinnaman, W. R., Nabinger, S. C., Heller, B. L., Herbert, B., Chan, R. J., & Wells, C. D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1995 · Cited by 61
“Because the proliferation of ductal mammary cells requires ERK1/2 dependent signaling [28], the relative levels of Amot protein were measured in a panel of human breast cell lines with differing hormone and growth factor receptor status [29].”
A New Human DSG2-Transgenic Mouse Model for Studying the Tropism and Pathology of Human Adenoviruses
Wang, H., Beyer, I., Persson, J., Song, H., Li, Z., Richter, M., Cao, H., van Rensburg, R., Yao, X., Hudkins, K. L., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00205-12 · Cited by 63
“Among the in vivo features that characterize EMT is the activation of Erk1/2 (MAPK) (81).”
BackgroundGuan, F., Schaffer, L., Handa, K., & Hakomori, S. (2010) · The FASEB Journal · doi:10.1096/fj.10-162107 · Cited by 64
Significance of myofibroblasts in oral squamous cell carcinoma
Thode, C., Jørgensen, T. G., Dabelsteen, E., Mackenzie, I. C., & Dabelsteen, S. (2011) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2010.00999.x · Cited by 64
Hongo, K., Tsuno, N. H., Kawai, K., Sasaki, K., Kaneko, M., Hiyoshi, M., Murono, K., Tada, N., Nirei, T., Sunami, E., et al. (2012) · Journal of Surgical Research · doi:10.1016/j.jss.2012.08.034 · Cited by 56
“[12] Turley EA, Veiseh M, Radisky DC, Bissell MJ.”
BackgroundDu, H., Gu, J., Peng, Q., Wang, X., Liu, L., Shu, X., He, Q., & Tan, Y. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/2337818 · Cited by 56
RetractedSung, C. O., Park, C.-K., & Kim, S. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.59 · Cited by 55
Qu, D., Johnson, J., Chandrakesan, P., Weygant, N., May, R. J., Aiello, N. M., Rhim, A. D., Zhao, L., Zheng, W., Lightfoot, S. A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118933 · Cited by 58
“EMT plays a key role in cancer invasion and metastasis [14,15].”
BackgroundUppaluri, R., Winkler, A. E., Lin, T., Law, J. H., Haughey, B. H., Nussenbaum, B. A., Paniello, R. C., Rich, J. T., Diaz, J. A., Michel, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1469 · Cited by 54
“We hypothesized that aggressive tumor growth mediated by these molecules may be due to their activity in putative cancer stem cells (CSCs) or cells undergoing an epithelial-to-mesenchymal (EMT) transition (14-17).”
BackgroundAkimoto, T., Fujiwara, N., Kagiya, T., Otsu, K., Ishizeki, K., & Harada, H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.11.112 · Cited by 52
LIN, Z.-H., Wang, L., Zhang, J., Liu, Y., Li, X., Guo, L., ZHANG, B., Zhu, W., & Ye, Q. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2455 · Cited by 50
Ral Overactivation in Malignant Peripheral Nerve Sheath Tumors
Bodempudi, V., Yamoutpoor, F., Pan, W., Dudek, A. Z., Esfandyari, T., Piedra, M., Babovick-Vuksanovic, D., Woo, R. A., Mautner, V. F., Kluwe, L., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01153-08 · Cited by 51
“These include growth factors, receptor tyrosine kinases, Ras and other small GTPases, Src, -catenin, and integrins (5, 63, 64).”
BackgroundPoly I:C induces collective migration of HaCaT keratinocytes via IL-8
Takada, K., Komine‐Aizawa, S., Hirohata, N., Trinh, Q. D., Nishina, A., Kimura, H., & Hayakawa, S. (2017) · BMC Immunology · doi:10.1186/s12865-017-0202-3 · Cited by 53
“In other hands, with the lack of constitutive activation of RAS signaling pathways, TGF-β1 induced an incomplete and transient mesenchymal conversion [56].”
Metadata
- Authors
- Turley, E. A., Veiseh, M., Radisky, D. C., & Bissell, M. J.
- Affiliations
- Western University (CA)
- Lawrence Berkeley National Laboratory (US)
- Mayo Clinic in Florida (US)
- Corresponding author
- Bissell, Mina J
- Venue
- Nature Clinical Practice Oncology
- Published
- 2008-03-18
- Volume
- 5
- Issue
- 5
- Pages
- 280-290
- ISSN
- 1743-4254 (ISSN-L)
- 1743-4262
- PMC
- PMC2846172
- OpenAlex
- W1972959587
- Cited by
- 253
- References
- 92
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 21 · 2020: 11 · 2019: 9 · 2018: 9 · 2017: 18 · 2016: 18 · 2015: 15 · 2014: 16 · 2013: 21 · 2012: 12
- FWCI
- 13.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Clinical Practice Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U54CA126552, R13CA113258, R37CA064786, R13CA098946, R01CA064786)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- epithelial-mesenchymal transition, cellular plasticity, tumor progression, tumor invasion, metastasis, ERK1/ERK2 signaling, PI3K signaling, Ras signaling, tumor microenvironment, fibrosis
- MeSH terms
- Cell Transformation, Neoplastic, Epithelial Cells, Humans, Neoplasms, Neoplastic Processes, Disease Progression, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.